Oncology

IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition

January 18th 2024

By Skylar Jeremias

The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.

SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy

January 17th 2024

By Skylar Jeremias

Article

As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.

Rituximab Biosimilars Effective in Treating Immune Thrombocytopenia

January 15th 2024

By Cameron Santoro

Article

A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia.

FDA Approves First Biosimilar for Neulasta Onpro

January 15th 2024

By Skylar Jeremias

Article

The FDA has approved Coherus Biosciences’ on-body injector version of Udenyca (pegfilgrastim-cbqv), making it the first biosimilar to reference Neulasta Onpro, the pegfilgrastim product that holds the majority of the pegfilgrastim market share.

Proposed Bevacizumab Biosimilar Demonstrates Clinical Equivalence to Avastin in NSCLC

January 13th 2024

By Deana Ferreri, PhD

Article

The proposed bevacizumab biosimilar BAT1706 (Bio-Thera Solutions) demonstrated equivalence to the reference product (Avastin) in a phase 3 comparative efficacy trial in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe

January 10th 2024

By Skylar Jeremias

Article

IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

January 4th 2024

By Skylar Jeremias

Article

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond

December 31st 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.

The Top 5 Most-Read Oncology Stories of 2023

December 27th 2023

By Skylar Jeremias

Article

The top 5 most-read oncology stories of 2023 include the US market launch of Fylnetra, the sixth pegfilgrastim biosimilar on the market, the FDA approval for an autoinjector pegfilgrastim biosimilar, and more.

FDA Approves Avzivi, the Fifth Biosimilar to Avastin

December 19th 2023

By Skylar Jeremias

Article

The FDA approved Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn), the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.